Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.

Carabia J, Carpio C, Abrisqueta P, Jiménez I, Purroy N, Calpe E, Palacio C, Bosch F, Crespo M.

Sci Rep. 2017 Sep 25;7(1):12262. doi: 10.1038/s41598-017-12135-7.

2.

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Purroy N, Wu CJ.

Cold Spring Harb Perspect Med. 2017 Apr 3;7(4). pii: a026740. doi: 10.1101/cshperspect.a026740. Review.

3.

Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.

Purroy N, Carabia J, Abrisqueta P, Egia L, Aguiló M, Carpio C, Palacio C, Crespo M, Bosch F.

Oncotarget. 2017 Jan 3;8(1):742-756. doi: 10.18632/oncotarget.13557.

5.

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.

Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.

Br J Haematol. 2015 Apr;169(2):188-98. doi: 10.1111/bjh.13273. Epub 2014 Dec 18.

PMID:
25521006
6.

Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.

Montes-Moreno S, Batlle A, de Villambrosía SG, Sánchez-Espiridión B, Cereceda L, González-Barca E, Purroy N, Pardal E, Martín A, Grande C, Mazorra F, Insunza A, Quero C, Aguiar D, Cruz MA, Rueda A, Llanos M, Codina JG, Arroyo FR, Caballero D, Conde E, López A, Provencio M, Piris M.

Haematologica. 2014 Aug;99(8):e138-41. doi: 10.3324/haematol.2014.104976. Epub 2014 Apr 24. No abstract available.

7.

Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.

Purroy N, Abrisqueta P, Carabia J, Carpio C, Calpe E, Palacio C, Castellví J, Crespo M, Bosch F.

Leukemia. 2014 Oct;28(10):1993-2004. doi: 10.1038/leu.2014.96. Epub 2014 Mar 12.

PMID:
24618734
8.

ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.

Calpe E, Purroy N, Carpio C, Abrisqueta P, Carabia J, Palacio C, Castellví J, Crespo M, Bosch F.

PLoS One. 2013 Dec 3;8(12):e81221. doi: 10.1371/journal.pone.0081221. eCollection 2013.

9.

ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.

Calpe E, Codony C, Baptista MJ, Abrisqueta P, Carpio C, Purroy N, Bosch F, Crespo M.

Blood. 2011 Oct 20;118(16):4401-10. doi: 10.1182/blood-2011-01-333682. Epub 2011 Aug 24.

PMID:
21865343

Supplemental Content

Loading ...
Support Center